Skip to main content
NCBI home page
Journal of Clinical Pathology logoLink to Journal of Clinical Pathology
. 1997 Apr;50(4):328–331. doi: 10.1136/jcp.50.4.328

The hormonal receptor status of uterine carcinosarcomas (mixed müllerian tumours): an immunohistochemical study.

A C Ansink 1, P A Cross 1, P Scorer 1, A de Barros Lopes 1, J M Monaghan 1
PMCID: PMC499885  PMID: 9215151

Abstract

AIM: To investigate the role of oestrogen and progesterone receptor status in uterine carcinosarcomas (mixed Müllerian tumours) to see whether the receptors were identifiable, and if so whether they were of significance clinically. METHODS: 11 cases of uterine carcinosarcoma were identified from clinical and pathology records. An immunohistochemical method was used to demonstrate oestrogen and progesterone hormone receptors on paraffin embedded material, with suitable tissue controls, staining being recorded. RESULTS: 10 of 11 cases showed staining for one or both hormone receptors in normal tissue adjacent to tumour. In four carcinosarcoma cases, staining for one or both receptors was shown within the epithelial component (appearing to correlate with the degree of epithelial differentiation); two of these cases had staining within sarcomatous areas. Two of the three patients still alive had epithelial hormone receptor positivity. CONCLUSIONS: Receptors for oestrogen and progesterone were found in four of 11 cases of uterine carcinosarcoma, using paraffin embedded material. There may be an association between hormone receptor positivity and clinical outcome.

Full text

PDF
328

Images in this article

330Image
on p.330
330Image
on p.330
331Image
on p.331

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Dunton C. J., Kelsten M. L., Brooks S. E., Viglione M. J., Carlson J. A., Mikuta J. J. Low-grade stromal sarcoma: DNA flow cytometric analysis and estrogen progesterone receptor data. Gynecol Oncol. 1990 May;37(2):268–275. doi: 10.1016/0090-8258(90)90346-m. [DOI] [PubMed] [Google Scholar]
  2. Gagné E., Têtu B., Blondeau L., Raymond P. E., Blais R. Morphologic prognostic factors of malignant mixed müllerian tumor of the uterus: a clinicopathologic study of 58 cases. Mod Pathol. 1989 Sep;2(5):433–438. [PubMed] [Google Scholar]
  3. George E., Lillemoe T. J., Twiggs L. B., Perrone T. Malignant mixed müllerian tumor versus high-grade endometrial carcinoma and aggressive variants of endometrial carcinoma: a comparative analysis of survival. Int J Gynecol Pathol. 1995 Jan;14(1):39–44. doi: 10.1097/00004347-199501000-00007. [DOI] [PubMed] [Google Scholar]
  4. Kahanpä K. V., Wahlström T., Gröhn P., Heinonen E., Nieminen U., Widholm O. Sarcomas of the uterus: a clinicopathologic study of 119 patients. Obstet Gynecol. 1986 Mar;67(3):417–424. [PubMed] [Google Scholar]
  5. Katz L., Merino M. J., Sakamoto H., Schwartz P. E. Endometrial stromal sarcoma: a clinicopathologic study of 11 cases with determination of estrogen and progestin receptor levels in three tumors. Gynecol Oncol. 1987 Jan;26(1):87–97. doi: 10.1016/0090-8258(87)90074-6. [DOI] [PubMed] [Google Scholar]
  6. Kerner H., Sabo E., Friedman M., Beck D., Samare O., Lichtig C. An immunohistochemical study of estrogen and progesterone receptors in adenocarcinoma of the endometrium and in the adjacent mucosa. Int J Gynecol Cancer. 1995 Jul;5(4):275–281. doi: 10.1046/j.1525-1438.1995.05040275.x. [DOI] [PubMed] [Google Scholar]
  7. Major F. J., Blessing J. A., Silverberg S. G., Morrow C. P., Creasman W. T., Currie J. L., Yordan E., Brady M. F. Prognostic factors in early-stage uterine sarcoma. A Gynecologic Oncology Group study. Cancer. 1993 Feb 15;71(4 Suppl):1702–1709. doi: 10.1002/cncr.2820710440. [DOI] [PubMed] [Google Scholar]
  8. Navarro D., Cabrera J. J., León L., Chirino R., Fernández L., López A., Rivero J. F., Fernández P., Falcón O., Jiménez P. Endometrial stromal sarcoma expression of estrogen receptors, progesterone receptors and estrogen-induced srp27 (24K) suggests hormone responsiveness. J Steroid Biochem Mol Biol. 1992 Mar;41(3-8):589–596. doi: 10.1016/0960-0760(92)90389-z. [DOI] [PubMed] [Google Scholar]
  9. Nisolle M., Casanas-Roux F., Wyns C., de Menten Y., Mathieu P. E., Donnez J. Immunohistochemical analysis of estrogen and progesterone receptors in endometrium and peritoneal endometriosis: a new quantitative method. Fertil Steril. 1994 Oct;62(4):751–759. doi: 10.1016/s0015-0282(16)57000-9. [DOI] [PubMed] [Google Scholar]
  10. Nyholm H. C., Christensen I. J., Nielsen A. L. Progesterone receptor levels independently predict survival in endometrial adenocarcinoma. Gynecol Oncol. 1995 Dec;59(3):347–351. doi: 10.1006/gyno.1995.9964. [DOI] [PubMed] [Google Scholar]
  11. Nyholm H. C., Nielsen A. L., Lyndrup J., Dreisler A., Thorpe S. M. Estrogen and progesterone receptors in endometrial carcinoma: comparison of immunohistochemical and biochemical analysis. Int J Gynecol Pathol. 1993 Jul;12(3):246–252. doi: 10.1097/00004347-199307000-00008. [DOI] [PubMed] [Google Scholar]
  12. O'Brien A. A., O'Briain D. S., Daly P. A. Aggressive endometrial stromal sarcoma responding to medroxyprogesterone following failure of tamoxifen and combination chemotherapy. Case report. Br J Obstet Gynaecol. 1985 Aug;92(8):862–866. doi: 10.1111/j.1471-0528.1985.tb03062.x. [DOI] [PubMed] [Google Scholar]
  13. Oláh K. S., Dunn J. A., Gee H. Leiomyosarcomas have a poorer prognosis than mixed mesodermal tumours when adjusting for known prognostic factors: the result of a retrospective study of 423 cases of uterine sarcoma. Br J Obstet Gynaecol. 1992 Jul;99(7):590–594. doi: 10.1111/j.1471-0528.1992.tb13827.x. [DOI] [PubMed] [Google Scholar]
  14. Sabini G., Chumas J. C., Mann W. J. Steroid hormone receptors in endometrial stromal sarcomas. A biochemical and immunohistochemical study. Am J Clin Pathol. 1992 Mar;97(3):381–386. doi: 10.1093/ajcp/97.3.381. [DOI] [PubMed] [Google Scholar]
  15. Snijders M. P., de Goeij A. F., Debets-Te Baerts M. J., Rousch M. J., Koudstaal J., Bosman F. T. Immunocytochemical analysis of oestrogen receptors and progesterone receptors in the human uterus throughout the menstrual cycle and after the menopause. J Reprod Fertil. 1992 Mar;94(2):363–371. doi: 10.1530/jrf.0.0940363. [DOI] [PubMed] [Google Scholar]
  16. Sutton G. P., Stehman F. B., Michael H., Young P. C., Ehrlich C. E. Estrogen and progesterone receptors in uterine sarcomas. Obstet Gynecol. 1986 Nov;68(5):709–714. [PubMed] [Google Scholar]
  17. Thornton J. G., Wells M. Oestrogen receptor in glands and stroma of normal and neoplastic human endometrium: a combined biochemical, immunohistochemical, and morphometric study. J Clin Pathol. 1987 Dec;40(12):1437–1442. doi: 10.1136/jcp.40.12.1437. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Tosi P., Sforza V., Santopietro R. Estrogen receptor content, immunohistochemically determined by monoclonal antibodies, in endometrial stromal sarcoma. Obstet Gynecol. 1989 Jan;73(1):75–78. [PubMed] [Google Scholar]
  19. Umpierre S. A., Burke T. W., Tornos C., Ordonez N., Levenback C., Morris M. Immunocytochemical analysis of uterine papillary serous carcinomas for estrogen and progesterone receptors. Int J Gynecol Pathol. 1994 Apr;13(2):127–130. doi: 10.1097/00004347-199404000-00004. [DOI] [PubMed] [Google Scholar]
  20. Wade K., Quinn M. A., Hammond I., Williams K., Cauchi M. Uterine sarcoma: steroid receptors and response to hormonal therapy. Gynecol Oncol. 1990 Dec;39(3):364–367. doi: 10.1016/0090-8258(90)90267-o. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Pathology are provided here courtesy of BMJ Publishing Group

RESOURCES